This has produced a response form the Director of the Association of the British Pharmaceutical Industry (ABPI). Nick tells me that a response from the authors is being written.
A key issue in this debate is the evidence of EoL interventions receiving greater weighting than non-EoL treatments. Evidence is mixed about weighting, although the most recent results from a survey of 3,969 respondents are negative. This work, was a collaboration between HEDS and OHE and is available for download as an OHE Research Paper. The feasibility work for study is available as a HEDS Discussion Paper.

Also, as highlighted in the ABPI response, the Policy Research Unit in Economic Evaluation of Health and Care Intervention (EEPRU) – a collaboration between HEDS and CHE - is finalising a wider project on societal weightings that is to inform the forthcoming value based pricing mechanism. We’ll let you know as soon as these results are publically available.
Photo credit: Images_of_Money via Flickr Creative Commons